Starling Oncology predicts $650 million in revenue and $6M adjusted EBITDA in 2026, targeting 100% revenue growth in 2027 (NASDAQ:STLN).
Starling Oncology predicts $650 million in revenue and $6M adjusted EBITDA in 2026, targeting 100% revenue growth in 2027 (NASDAQ:STLN).
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in